Zhejiang Shouxiangu Pharmaceutical Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Zhen-Yu Li

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.5yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Weak Statutory Earnings May Not Tell The Whole Story For Zhejiang Shouxiangu Pharmaceutical (SHSE:603896)

May 02

CEO

Zhen-Yu Li (33 yo)

2.5yrs

Permanencia

CN¥433,300

Compensación

Mr. Zhen-Yu Li serves as Managing Director of Zhejiang Shouxiangu Pharmaceutical Co., Ltd. since April 22, 2022.

Zhejiang Shouxiangu Pharmaceutical Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Zhejiang Shouxiangu Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

No independent directors

Recent updates

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2023)

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Weak Statutory Earnings May Not Tell The Whole Story For Zhejiang Shouxiangu Pharmaceutical (SHSE:603896)

First quarter 2024 earnings released: EPS: CN¥0.39 (vs CN¥0.32 in 1Q 2023)

Zhejiang Shouxiangu Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 15%

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 3Q 2022)

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHSE:603896) agreed to acquire Hangzhou Yunhe Hengli Commercial Real Estate Co., Ltd from Hangzhou Yunhe Group Construction Management Co., Ltd. for CNY 0.001 million.

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.13 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.13 in 2Q 2022)

New minor risk - Shareholder dilution

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 30% to CN¥83.20

Full year 2022 earnings: Revenues miss analyst expectations

No independent directors

Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.16 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.071 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.071 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.092 (vs CN¥0.064 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.23 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.07 (vs CN¥0.88 in FY 2019)

New 90-day low: CN¥33.89

Investor sentiment deteriorated over the past week

New 90-day low: CN¥37.87

New 90-day high: CN¥48.05

Market bids up stock over the past week

New 90-day high: CN¥43.80

Third quarter earnings released

New 90-day high - CN¥41.12

Earnings released

New 90-day high - CN¥40.33

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Permanencia

Compensación